"The increased use of GLP-1 medications presents an exciting opportunity to support Americans managing diabetes and weight loss, as well as those seeking to lead a healthier lifestyle," Bob Nolan, the vice president of demand science at Conagra Brands, shared in a statement
Through this mid-year update, we shed light on several key areas: GLP-1 agonists have emerged as a significant driver of prescription drug spending, with diabetes and obesity among the top contributors
But remember, this should not replace individual medical advice
Supplements and prescription medications are fundamentally different categories with different mechanisms, regulatory standards, and evidence bases
The degeneration may be in the form of lesions in the central nervous system, as in multiple system atrophy (MSA), or in loss of autonomic nerves not involving the central nervous system, as in pure autonomic failure (PAF)